Literature DB >> 28453802

Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.

Arthur Kostron1, Martina Friess1, Ilhan Inci1, Sven Hillinger1, Didier Schneiter1, Hans Gelpke1, Rolf Stahel2, Burkhardt Seifert3, Walter Weder1, Isabelle Opitz1.   

Abstract

OBJECTIVES: The objective of this retrospective study was to assess perioperative outcomes, overall survival and freedom from recurrence after induction chemotherapy followed by extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) in patients with mesothelioma in a propensity score matched analysis.
METHODS: Between September 1999 and August 2015, 167 patients received multimodality treatment (platinum-based chemotherapy followed by EPP [ n =  141] or P/D [ n =  26]). We performed 2:1 propensity score matching for gender, laterality, epithelioid histological subtype and International Mesothelioma Interest Group (iMig) stage (52 EPP and 26 P/D).
RESULTS: Postoperative major morbidity (48% vs 58%, P =  0.5) was similar in both groups; however, the complication profile and severity were different and favoured P/D; the 90-day mortality (8% vs 0%, P =  0.3) rate was lower in P/D although not statistically significant. Prolonged air leak (≥10 days) occurred in 15 patients (58%) undergoing P/D. The intensive care unit stay was significantly longer after EPP ( P =  0.001). Freedom from recurrence was similar for both groups (EPP: median 15 months, 95% confidence interval [CI]: 10-21; P/D: 13 months, 95% CI: 11-17) ( P =  0.2). Overall survival was significantly longer for patients undergoing P/D (median 32 months, 95% CI: 29-35) compared to EPP (23 months, 95% CI: 21-25) ( P =  0.031), but in the P/D group many cases were censored (73%) and the follow-up time was relatively short.
CONCLUSIONS: P/D and EPP seem to have similar rates of major morbidity, although the profile of complications is different and more severe after EPP. Freedom from recurrence is comparable in both groups whereas improved overall survival needs to be confirmed in a large patient group with longer follow-up.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Extrapleural pneumonectomy; Mesothelioma; Pleurectomy/decortication; Propensity score matching

Mesh:

Year:  2017        PMID: 28453802     DOI: 10.1093/icvts/ivw422

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  11 in total

1.  Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.

Authors:  Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; Kalliopi Athanassiadi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-29

Review 2.  Extrapleural pneumonectomy: still indicated?

Authors:  Andreas Domen; Lawek Berzenji; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2018-10

3.  Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Ryotaro Kamohara; Go Hatachi; Takeshi Nagayasu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-01-23       Impact factor: 1.520

4.  Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?

Authors:  Servet Bölükbas; Michael Eberlein
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR).

Authors:  Dimitrios E Magouliotis; Prokopis-Andreas Zotos; Arian Arjomandi Rad; Despoina Koukousaki; Vasiliki Vasilaki; Ioustini Portesi; Kyriakos Spiliopoulos; Thanos Athanasiou
Journal:  Updates Surg       Date:  2022-09-03

6.  The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis.

Authors:  Olivia Lauk; Karina Bruestle; Thomas Neuer; Bianca Battilana; Thi Dan Linh Nguyen; Thomas Frauenfelder; Rolf Stahel; Walter Weder; Alessandra Curioni-Fontecedro; Isabelle Opitz
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

7.  Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

Authors:  Luis E De León; Carlos E Bravo-Iñiguez; Sam Fox; Jeffrey Tarascio; Samuel Freyaldenhoven; Moshe Lapidot; Michael T Jaklitsch; Raphael Bueno
Journal:  J Thorac Cardiovasc Surg       Date:  2020-01-30       Impact factor: 5.209

8.  Long-term outcomes after lung-sparing surgery for epithelial mesothelioma.

Authors:  Cristiano Breda; Simone Furia; Giuseppe Lucchini; Antonio Zaccaria; Enrico Verderi; Giuseppe Natale; Fabio Lo Giudice; Roberta Cavallin; Andrea Ferronato; Paolo Fontana
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

9.  Induction Chemotherapy Followed by Pleurectomy Decortication and Hyperthermic Intraoperative Chemotherapy (HITHOC) for Early-Stage Epitheliod Malignant Pleural Mesothelioma-A Prospective Report.

Authors:  Stefano Bongiolatti; Francesca Mazzoni; Ottavia Salimbene; Enrico Caliman; Carlo Ammatuna; Camilla E Comin; Lorenzo Antonuzzo; Luca Voltolini
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

10.  Quality of Life Is Not Deteriorated After Extrapleural Pneumonectomy vs. (Extended) Pleurectomy/Decortication in Patients With Malignant Pleural Mesothelioma.

Authors:  Olivia Lauk; Miriam Patella; Thomas Neuer; Ilhan Inci; Walter Weder; Isabelle Opitz
Journal:  Front Surg       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.